Which countries are allowing Named Patients Sales ?
Due to difference in legislation, EAPs to Orphan Drugs vary much across Europe. The following map shows, where NPS/EAP are possible in principle. You will note that countries allowing EAP from Phase II represent a total population of more than 210M inhabitants.
To start your Early Access Program in countries of your choice, please contact us at: firstname.lastname@example.org